Please select the option that best describes you:
Topics:
Thoracic Malignancies • Medical Oncology
Is there any benefit to adding bevacizumab to chemo-immunotherapy in metastatic NSCLC?
For the Impower 150 trial, is there data reported on PFS and OS for ABCP vs ACP (atezolizumab/bevacizumab/carboplatin/paclitaxel vs atezolizumab/carboplatin/paclitaxel)?
Answer from: Medical Oncologist at Academic Institution
In the ITT population of the Impower 150 trial the median OS was 19.2 mo on arm B (Atezo + chemo + bev) and 14.7 mo on arm C (chemo + bev) with a Significant HR of 0.78 but the mOS in arm A (atezo + chemo) was 19.4 mo with no planned comparison to arm B but seems...
Sign in or Register to read more
Answer from: Medical Oncologist at Academic Institution
With further follow-up we may see differences in mOS between arms A+B of IMpower 150 (which may not be surprising given what we know about the addition of bevacizumab to paclitaxel/carboplatin from ECOG 4599), and no statistical comparison of arms A+B was planned as part of this trial. The more rel...
Answer from: Medical Oncologist at Academic Institution
There appears to be early hints that adding bevacizumab may have some role based on the comparative HRs.
In the ITT-WT population, the HR for OS was 0.78 (95% CI 0.64-0.96, p=0.016) with the bev+IO+Chemo arm in relation to control chemo+Bev group compared to HR for OS of 0.88 (95% CI...